Supernus Pharmaceuticals (SUPN) EBITDA (2011 - 2026)
Supernus Pharmaceuticals' EBITDA was -$32.22 million in Q2 2026, compared with $33.5 million a year earlier.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) EBITDA (2011 - 2026) Analysis & Trends
On a trailing twelve-month basis, Supernus Pharmaceuticals' EBITDA was -$13.06 million through Jun 30, 2026; for FY2025, it came in at $29.28 million, down 81.9% from FY2024.
- EBITDA shows a five-year compound annual growth rate of -31.3% (FY2020 to FY2025).
- In earlier years, EBITDA was $162.08 million in FY2024 (+103.6%), $79.59 million in FY2023 (-39.6%), $131.67 million in FY2022 (+11.0%) and $118.62 million in FY2021 (-38.2%).
- Quarterly EBITDA has moved between -$35.43 million (Q3 2025) and $60.95 million (Q3 2024) over five years.
- Compared with a year earlier, EBITDA was higher in two of the last five quarters, with growth averaging 17.0%.
- The best year-over-year quarter for EBITDA over five years was Q4 2022 (growth of 193.4%); the worst was Q2 2023 (a decline of 90.5%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 12.29 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 9.10 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 8.33 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 999.00 Mn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 5.09 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 4.63 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -9.70 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 5.89 Bn |
| 10 | Supernus Pharmaceuticals | 2.39 Bn | 1.04 Bn | 185.39 Mn | -32.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.22 Mn |
| Dec 31, 2025 | 21.08 Mn |
| Sep 30, 2025 | -35.43 Mn |
| Jun 30, 2025 | 33.50 Mn |
| Mar 31, 2025 | 10.13 Mn |
| Dec 31, 2024 | 40.25 Mn |
| Sep 30, 2024 | 60.95 Mn |
| Jun 30, 2024 | 43.29 Mn |
| Mar 31, 2024 | 17.60 Mn |
| Dec 31, 2023 | 20.68 Mn |
| Sep 30, 2023 | 30.00 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 26.31 Mn |
| Dec 31, 2022 | 55.71 Mn |
| Sep 30, 2022 | 20.78 Mn |
| Jun 30, 2022 | 33.40 Mn |
| Mar 31, 2022 | 23.86 Mn |
| Dec 31, 2021 | 23.27 Mn |
| Sep 30, 2021 | 43.68 Mn |
| Jun 30, 2021 | 45.03 Mn |
API Access
Supernus Pharmaceuticals EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();